Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease

Vascular Health and Risk Management

Volumn 12, Issue , 2016, Pages 341-356

  Herten, Monika ^a   Torsello, Giovanni B ^a,b   Schönefeld, Eva ^a   Stahlhoff, Stefan ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

Critical limb ischemia; Drug coated balloon; Peripheral artery disease; Restenosis, atherectomy; Stent restenosis

Indexed keywords

ARTERY DISEASE; ARTERY PROSTHESIS; ATHERECTOMY; ATHERECTOMY CATHETER; BARE METAL STENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEVICE SAFETY; DRUG ELUTING STENT; FEMORAL POPLITEAL ARTERIAL DISEASE; FOLLOW UP; HUMAN; INFRAINGUINAL PERIPHERAL ARTERY DISEASE; JETSTREAM ATHERECTOMY DEVICE; LASER SURGERY; META ANALYSIS (TOPIC); MICRO INFUSION CATHETER; NONHUMAN; ORBITAL ATHERECTOMY DEVICE; PACLITAXEL COATED BALLOON; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; RESTENOSIS; REVIEW; ROTATIONAL ATHERECTOMY DEVICE; SILVERHAWK; SUPERFICIAL FEMORAL ARTERY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TURBOHAWK; ADVERSE EFFECTS; CRITICAL ILLNESS; DEVICES; DIAGNOSTIC IMAGING; EQUIPMENT DESIGN; FEMORAL ARTERY; ISCHEMIA; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; STENOSIS, OCCLUSION AND OBSTRUCTION; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT; PACLITAXEL;

ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; CRITICAL ILLNESS; EQUIPMENT DESIGN; FEMORAL ARTERY; HUMANS; ISCHEMIA; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 84984868978     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S81122     Document Type: Review

References (72)

1. Conrad MF, Kang J, Cambria RP, et al.Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease.J Vasc Surg.2009;50(4):799-805.
2. Mwipatayi BP, Hockings A, Hofmann M, Garbowski M, Sieunarine K.Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: A meta-analysis.J Vasc Surg.2008; 47(2):461-469.
3. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML.Biological responses in stented arteries.Cardiovasc Res.2013;99(2):353-363.
4. Creel CJ, Lovich MA, Edelman ER.Arterial paclitaxel distribution and deposition.Circ Res.2000;86(8):879-884.
5. Levin AD, Vukmirovic N, Hwang CW, Edelman ER.Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.Proc Natl Acad Sci USA.2004;101(25):9463-9467.
6. Axel DI, Kunert W, Goggelmann C, et al.Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.Circulation.1997;96(2):636-645.
7. Kelsch B, Scheller B, Biedermann M, et al.Dose response to paclitaxelcoated balloon catheters in the porcine coronary overstretch and stent implantation model.Invest Radiol.2011;46(4):255-263.
8. Cremers B, Speck U, Kaufels N, et al.Drug-eluting balloon: Very shortterm exposure and overlapping.Thromb Haemost.2009;101(1):201-206.
9. Margolis J, McDonald J, Heuser R, et al.Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): A first-in-human safety and dose-finding study.Clin Cardiol.2007;30(4):165-170.
10. Gray W.Are all DCB equal? LINC Leipzig, Germany; 2015.Available from: http://linc2015.cloudcontrolled.com/media/15t_1_1420_Gray.pdf.Accessed February 19, 2015.
11. Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B.Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model.Clin Res Cardiol.2009;98(5):325-330.
12. Bondesson P, Lagerqvist B, James SK, Olivecrona GK, Venetsanos D, Harnek J.Comparison of two drug-eluting balloons: A report from the SCAAR registry.EuroIntervention.2012;8(4):444-449.
13. Tepe G.DCBs: look to the data.LINC Today-the official newspaper of LINC.2015 (Issue 1):4.
14. Tepe G, Zeller T, Albrecht T, et al.Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.N Engl J Med.2008; 358(7):689-699.
15. Werk M, Langner S, Reinkensmeier B, et al.Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon:femoral paclitaxel randomized pilot trial.Circulation.2008; 118(13):1358-1365.
16. Werk M, Albrecht T, Meyer DR, et al.Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial.Circ Cardiovasc Interv.2012;5(6):831-840.
17. Scheinert D, Duda S, Zeller T, et al.The LEVANT I (Lutonix paclitaxelcoated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.JACC Cardiovasc Interv.2014;7(1):10-19.
18. Cassese S, Byrne RA, Ott I, et al.Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: A meta-analysis of randomized trials.Circ Cardiovasc Interv.2012;5(4):582-589.
19. Rosenfield K, Jaff MR, White CJ, et al; LEVANT 2 Investigators.Trial of a paclitaxel-coated balloon for femoropopliteal artery disease.N Engl J Med.2015;373(2):145-153.
20. Tepe G, Laird J, Schneider P, et al.IN.PACT SFA Trial Investigators.Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA Randomized Trial.Circulation.2015;131(5):495-502.
21. Duda S.ILLUMENATE FIH: direct DCB cohort-first results.LINC Leipzig, Germany; 2015.Available from: http://linc2015.cloudcontrolled.com/media/15th_1_0830_Duda.pdf.Accessed February 19, 2015.
22. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S.Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study.Catheter Cardiovasc Interv.2015;86(2):278-286.
23. Tepe G, Schnorr B, Albrecht T, et al.Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER Trial.JACC Cardiovasc Interv.2015;8(1 Pt A):102-108.
24. Tepe G, Zeller T, Schnorr B, et al.High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: An additional analysis from the THUNDER study.J Endovasc Ther.2013;20(6):792-800.
25. Fanelli F, Cannavale A, Boatta E, et al.Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial.J Endovasc Ther.2012;19(5):571-580.
26. Zeller T, Baumgartner I, Scheinert D, et al.IN.PACT DEEP Trial Investigators.Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia:12-month results from the IN.PACT DEEP randomized trial.J Am Coll Cardiol.2014;64(15):1568-1576.
27. Liistro F, Porto I, Angioli P, et al.Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK):a randomized trial in diabetic patients with critical limb ischemia.Circulation.2013;128(6):615-621.
28. Zeller T, Beschorner U, Pilger E, et al.Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs.the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries).JACC Cardiovasc Interv.2015;8(12):1614-1622.
29. Schmidt A, Piorkowski M, Werner M, et al.First experience with drugeluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome.J Am Coll Cardiol.2011;58(11):1105-1109.
30. Steiner S.German single center experience with Lutonix DCB in BTK.LINC Leipzig, Germany; 2015.Available from: http://linc2015.cloudcontrolled.com/media/15w_1_1454__S.%20Steiner.pdf.Accessed February 19, 2015.
31. Stabile E, Virga V, Salemme L, et al.Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis.J Am Coll Cardiol.2012;60(18):1739-1742.
32. Liistro F, Grotti S, Porto I, et al.Drug-eluting balloon in peripheral intervention for the superficial femoral artery: The DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).JACC Cardiovasc Interv.2013;6(12):1295-1302.
33. Tepe G.The Copa Cabana study: DEB vs.POBA in in-stent restenosis.LINC, Leipzig, Germany; 2015.Available from: http://linc2015.cloudcontrolled.com/media/15t_1_1620_Tepe.pdf.Accessed February 19, 2015.
34. Krankenberg H, Tubler T, Ingwersen M, et al.Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis:the randomized femoral artery in-stent restenosis (FAIR) Trial.Circulation.2015;132(23):2230-2236.
35. Liistro F, Angioli P, Porto I, et al.Paclitaxel-eluting balloon vs.standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: The DEBATE-ISR study.J Endovasc Ther.2014;21(1):1-8.
36. Krankenberg H.DCB and ISR: Inside from the FAIR study.LINC Leipzig, Germany; 2015.Available from: http://linc2015.cloudcontrolled.com/media/15t_1_1410_Krankenberg.pdf.Accessed February 19, 2015.
37. Grotti S, Liistro F, Angioli P, et al.Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries:three-year results of the DEBATE-ISR study.J Endovasc Ther.2016;23(1):52-57.
38. Tosaka A, Soga Y, Iida O, et al.Classification and clinical impact of restenosis after femoropopliteal stenting.J Am Coll Cardiol.2012; 59(1):16-23.
39. Herten M, Torsello GB, Schonefeld E, Imm B, Osada N, Stahlhoff S.Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.J Vasc Surg.2015;61(2):394-399.
40. Schnorr B, Kelsch B, Cremers B, Clever YP, Speck U, Scheller B.Paclitaxel-coated balloons-survey of preclinical data.Minerva Cardioangiol.2010;58(5):567-582.
41. Yahagi K, Otsuka F, Sakakura K, et al.Pathophysiology of superficial femoral artery in-stent restenosis.J Cardiovasc Surg (Torino).2014;55(3):307-323.
42. Van den Berg JC.Towards a better understanding and more efficient treatment of in-stent restenosis.J Cardiovasc Surg (Torino).2014; 55(3):305-306.
43. Fanelli F, Cannavale A, Gazzetti M, et al.Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease.Cardiovasc Intervent Radiol.2014;37(4):898-907.
44. Tepe G, Beschorner U, Ruether C, et al.Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium.J Endovasc Ther.2015;22(5):727-733.
45. Al Khoury G, Chaer R.Evolution of atherectomy devices.J Cardiovasc Surg (Torino).2011;52(4):493-505.
46. Quevedo HC, Arain SA, Ali G, Abi Rafeh N.A critical view of the peripheral atherectomy data in the treatment of infrainguinal arterial disease.J Invasive Cardiol.2014;26(1):22-29.
47. Adams GL, Khanna PK, Staniloae CS, Abraham JP, Sparrow EM.Optimal techniques with the Diamondback 360 degrees system achieve effective results for the treatment of peripheral arterial disease.J Cardiovasc Transl Res.2011;4(2):220-229.
48. Beschorner U, Zeller T.Combination of mechanical atherectomy and drug-eluting balloons for femoropopliteal in-stent restenosis.J Cardiovasc Surg (Torino).2014;55(3):347-349.
49. Rastan A, McKinsey JF, Garcia LA, et al.One-year outcomes following directional atherectomy of infrapopliteal artery lesions: Subgroup results of the prospective, multicenter DEFINITIVE LE Trial.J Endovasc Ther.2015;22(6):839-846.
50. Diamantopoulos A, Katsanos K.Atherectomy of the femoropopliteal artery: A systematic review and meta-analysis of randomized controlled trials.J Cardiovasc Surg (Torino).2014;55(5):655-665.
51. Sixt S, Carpio Cancino OG, Treszl A, et al.Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries.J Vasc Surg.2013;58(3):682-686.
52. Gandini R, Del Giudice C, Merolla S, Morosetti D, Pampana E, Simonetti G.Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: A single-center, prospective, randomized study.J Endovasc Ther.2013;20(6):805-814.
53. Tepe G.DCB +atherectomy for complex lesions: DEFINITIVE AR-final data.LINC, Leipzig, Germany; 2015.Available from: http://linc2015.cloudcontrolled.com/media/15t_1_1005_Tepe.pdf.Accessed February 19, 2015.
54. Diehm N, Schneider H.Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions.J Endovasc Ther.2013;20(6):819-825.
55. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR.Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany.Catheter Cardiovasc Interv.2014;84(4):546-554.
56. Pietzsch JB, Geisler BP, Zeller T.Endovascular interventions for treatment of femoropopliteal peripheral artery disease: updated budget impact analysis for Germany based on latest clinical evidence.Value Health.2015;18(7):A349.
57. Zeller T, Rastan A, Macharzina R, et al.Drug-coated balloons vs.drugeluting stents for treatment of long femoropopliteal lesions.J Endovasc Ther.2014;21(3):359-368.
58. Fusaro M, Cassese S, Ndrepepa G, et al.Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: A meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison.Int J Cardiol.2013;168(4):4002-4009.
59. Bosiers M, Peeters P, Tessarek J, Deloose K, Strickler S.Zilver PTX Single-Arm Study Investigators.The Zilver(R) PTX(R) Single Arm Study: 12-month results from the TASC C/D lesion subgroup.J Cardiovasc Surg (Torino).2013;54(1):115-122.
60. Dake MD, Ansel GM, Jaff MR, et al.Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.J Am Coll Cardiol.2013;61(24):2417-2427.
61. Katsanos K, Spiliopoulos S, Karunanithy N, Krokidis M, Sabharwal T, Taylor P.Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.J Vasc Surg.2014;59(4):1123-1133.
62. Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D.Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: The IDEAS randomized controlled trial.JACC Cardiovasc Interv.2014;7(9):1048-1056.
63. Singh GD, Armstrong EJ, Laird JR.Femoropopliteal in-stent restenosis:current treatment strategies.J Cardiovasc Surg (Torino).2014;55(3):325-333.
64. Werner M, Scheinert D, Henn M, et al.Endovascular brachytherapy using liquid Beta-emitting rhenium-188 for the treatment of longsegment femoropopliteal in-stent stenosis.J Endovasc Ther.2012;19(4):467-475.
65. Dick P, Sabeti S, Mlekusch W, et al.Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: Initial experience.Radiology.2008;248(1):297-302.
66. Karthik S, Tuite DJ, Nicholson AA, et al.Cryoplasty for arterial restenosis.Eur J Vasc Endovasc Surg.2007;33(1):40-43.
67. Wildgruber MG, Berger HJ.Cryoplasty for the prevention of arterial restenosis.Cardiovasc Intervent Radiol.2008;31(6):1050-1058.
68. Shin SH, Baril DT, Chaer RA, Makaroun MS, Marone LK.Cryoplasty offers no advantage over standard balloon angioplasty for the treatment of in-stent stenosis.Vascular.2013;21(6):349-354.
69. Bosiers M, Deloose K, Callaert J, et al.Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: Twelve-month results from a multicenter randomized trial.J Endovasc Ther.2015;22(1):1-10.
70. Zeller T, Dake MD, Tepe G, et al.Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.JACC Cardiovasc Interv.2013;6(3):274-281.
71. Owens CD [webpage on the Internet].LINC Leipzig, Germany; 2016.Available from: https://linc2016.app.exo.io/media/1040_Christopher_ Owens_26_01_2016_Room_1___Main_Arena_1.pdf.Accessed March 31, 2016.
72. Herten M, Schönefeld E, Stahlhoff S, Schwindt A, Torsello GB.Drugcoated balloons in the treatment of femoro-and infra-popliteal lesions.Interv Cardiol.2015;7(4):353-370.